30APR10 DS product portfolio

合集下载

Blue Coat Systems PacketShaper 11.6 第三方版权声明说明书

IPv6 Classification
PacketShaper 11.6
Third Party Copyright Notices
© 2016 Blue Coat Systems, Inc. All rights reserved. BLUE COAT, PROXYSG, PACKETSHAPER, CACHEFLOW, INTELLIGENCECENTER, CACHEOS, CACHEPULSE, CROSSBEAM, K9, DRTR, MACH5, PACKETWISE, POLICYCENTER, PROXYAV, PROXYCLIENT, SGOS, WEBPULSE, SOLERA NETWORKS, DEEPSEE, DS APPLIANCE, SEE EVERYTHING. KNOW EVERYTHING., SECURITY EMPOWERS BUSINESS, BLUETOUCH, the Blue Coat shield, K9, and Solera Networks logos and other Blue Coat logos are registered trademarks or trademarks of Blue Coat Systems, Inc. or its affiliates in the U.S. and certain other countries. This list may not be complete, and the absence of a trademark from this list does not mean it is not a trademark of Blue Coat or that Blue Coat has stopped using the trademark. All other trademarks mentioned in this document owned by third parties are the property of their respective owners. This document is for informational purposes only. BLUE COAT MAKES NO WARRANTIES, EXPRESS, IMPLIED, OR STATUTORY, AS TO THE INFORMATION IN THIS DOCUMENT. BLUE COAT PRODUCTS, TECHNICAL SERVICES, AND ANY OTHER TECHNICAL DATA REFERENCED IN THIS DOCUMENT ARE SUBJECT TO U.S. EXPORT CONTROL AND SANCTIONS LAWS, REGULATIONS AND REQUIREMENTS, AND MAY BE SUBJECT TO EXPORT OR IMPORT REGULATIONS IN OTHER COUNTRIES. YOU AGREE TO COMPLY STRICTLY WITH THESE LAWS, REGULATIONS AND REQUIREMENTS, AND ACKNOWLEDGE THAT YOU HAVE THE RESPONSIBILITY TO OBTAIN ANY LICENSES, PERMITS OR OTHER APPROVALS THAT MAY BE REQUIRED IN ORDER TO EXPORT, RE-EXPORT, TRANSFER IN COUNTRY OR IMPORT AFTER DELIVERY TO YOU. Americas: Blue Coat Systems, Inc. 384 Santa Trinita Avenue Sunnyvale, CA 94085

有关钱的单词100个

有关钱的单词100个1. Money - 钱2. Cash - 现金3. Currency - 货币4. Banknote - 钞票5. Coin - 硬币6. Wallet - 钱包7. Credit card - 信用卡8. Debit card - 借记卡9. Bank account - 银行账户10. Savings - 储蓄11. Checking account - 支票账户12. ATM - 自动取款机13. Withdrawal - 取款14. Deposit - 存款15. Transaction - 交易16. Interest rate - 利率17. Loan - 贷款18. Mortgage - 抵押贷款19. Investment - 投资20. Budget - 预算21. Bill - 账单22. Income - 收入23. Expense - 开支24. Balance - 余额25. Profit - 利润26. Loss - 损失27. Salary - 工资28. Tax - 税29. Inflation - 通货膨胀30. Exchange rate - 汇率31. Financial - 金融的32. Wealth - 财富33. Poverty - 贫困34. Prosperity - 繁荣35. Donation - 捐赠36. Fees - 费用37. Interest - 利息38. Insurance - 保险39. Retirement - 退休40. Stock - 股票41. Dividend - 股息42. Entrepreneur - 企业家43. Inheritance - 遗产44. Overdraft - 透支45. Remittance - 汇款46. Diversification - 多元化47. Capital - 资本48. Venture - 冒险49. Exchange - 交换50. Bull market - 牛市51. Bear market - 熊市52. Stock market - 股市53. Bond - 债券54. Mutual fund - 共同基金55. Real estate - 房地产56. Economic - 经济的57. Invoice - 发票58. Entrepreneurship - 创业59. Deductible - 免赔额60. Transaction fee - 交易费61. Budgeting - 预算编制62. Foreign exchange - 外汇63. Counterfeit - 伪造的64. Financial advisor - 财务顾问65. Fiscal - 财政的66. Utility bill - 水电费账单67. Principal - 本金68. Interest payment - 利息支付69. Economic growth - 经济增长70. Payroll - 工资单71. Gross income - 总收入72. Net worth - 净资产73. Credit score - 信用评分74. Collateral - 抵押品75. Bankruptcy - 破产76. Development - 开发77. Recession - 经济衰退78. Indebted - 负债的79. Investment portfolio - 投资组合80. Financial statement - 财务报表81. Refund - 退款82. Coupon - 优惠券83. Invoice - 发票84. Entrepreneurship - 创业85. Deductible - 免赔额86. Money order - 汇票87. Payment - 付款88. Prosperity - 繁荣89. Cryptocurrency - 加密货币90. Economic indicator - 经济指标91. Annual percentage rate (APR) - 年利率92. Capital gains - 资本利得93. Recession - 经济衰退94. Unemployment - 失业95. Savings account - 储蓄账户96. Loan repayment - 贷款还款97. Asset - 资产98. Liability - 负债99. Bearish - 看空的100. Portfolio - 投资组合。

Repower5MW 风机[1]

5 MW
• 叶轮直径 Rotor diameter:126 m
• 轮毂高度 Hub heights:
•陆上型 Onshore: 120 m
•离岸型 Offshore: 85 – 100 m
世界上最大的叶片—LM61.5
世界上最大的风机
世界上最大的风机
5MW样机的组装 Assembly of the 5M Prototype
0 0
测量结果 Measurements
Guaranteed and Measured Power Curves REpower 5M
REpower 5M功率曲线保证值和测量值的比较
比预测值高1-3%
5
guaranteed el. Power (kW)
10
15
wind speed at hub height (m/s)
指
标
99%
98% 98% 98%
98%
97%
96%
95%
80
85%
2005年2月以来，平均 95.3%
70 Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan
Month
月份
%
el. Power (kW) - medium voltage path
6000 5000 4000 3000 2000 1000
¾ 冗余设计及更加完善的安全保障 Designed with redundancies and extended safety factors
¾ 结合法兰的模块化传动系统 Modular drive train with flanges
¾ 主轴双轴承设计 Double bearing of main shaft

雀巢收购惠氏

Analysis of Nestle-Wyeth Acquisition Deal浅析雀巢—惠氏收购案国贸093 柳飘然 2009014315内容简介：2012年4月23日，“并购狂人”雀巢上演生命中最辉煌的一刻：以118.5亿美元收购了婴幼儿奶粉品牌——惠氏（即辉瑞旗下的营养品业务)！业界评价称，此宗收购案成为今年迄今为止最大规模的交易之一。

收购后的雀巢有望一跃成为中国最大的婴儿奶粉供应商，可以在有利可图的婴儿配方奶市场抢占先机，并将对中国婴儿奶粉行业产生重要影响。

关键词：收购acquisition，雀巢Nestle，惠氏Wyeth，婴儿配方奶粉市场baby milk formula market Switzerland-based Nestle, the world’s largest food giant, agreed on 23 Apr 2012 to acquire Wyeth baby formula business from Pfizer, the world’s largest drug manufacturer, in a deal of 11.85 billion U.S. dollars. As a strategic move to enhance the company’s status in the global field of infant nutrition business. The acquisition means that Nestl e wins the bid and it can forestall the lucrative infant formula market now.1 The Introduction of the Two Parties1.1A brief introduction to NestleNestle is the world’s leading nutrition, health and wellness company. Nestl e with headquarters in Vevey, Switzerland. It was founded in 1866 by Henri Nestle. And it means “Little Birds Nest”,standing for love, security, natural and nutrition. Their mission of "Good Food, Good Life" is to provide consumers with the best tasting, most nutritious choices in a wide range of food and beverage categories and eating occasions, from morning to night. Their brands are : Bottled water, Baby foods, Chocolate , Coffee, Dairy, Drinks, Ice cream and so on.The company is based on sound human values and principles. The Nestle Corporate Business Principles are at the basis of their company’s culture, developed over 140 years, wh ich reflects the ideas of fairness, honesty and long-term thinking. They employ around 328 000 people and have factories or operations in almost every country in the world. Nestle sales for 2011 were almost CHF 83.7 bn.1.2 A brief introduction to WyethWyeth, formerly one of the companies owned by American Home Products Corporation (AHP), was a pharmaceutical company. The company was based in Madison, New Jersey, USA. On January 25,2009 .The Wall Street Journal reported that Pfizer agreed to buy Wyeth at a cost of US$68 billion. a deal financed with cash, shares and loans. The deal was completed on October 15, 2009.Hence Wyeth is part of Pfizer.Pfizer Inc: Evolving to meet the needs of a changing society. Since Pfizer was founded by cousins Charles Pfizer and Charles Erhart in 1849, their pharmaceutical company has remained dedicated to discovering and developing new, and better, ways to prevent and treat disease and improve health and well being for people around the world.2 The Reasons for the Acquisition2.1 The Reasons for Nestle◆To maximize market share in Asia-pacificThe last few years, Europe and the United States and other countries infant food market becomes saturated, and the prospects for development in the Asia-Pacific market and plenty of room, especially the Asia-Pacific region the number of infants and young children most market growth prospects. The smaller Wyeth, with 60 percent of its sales are in emerging markets (Asia-Pacific), many of them with large, fast-growing populations..Wyeth's business in Asia as key since the region accounts for 45 percent of the world milk formula market -- China alone accounts for a fifth of global sales .In a strategic move to enhance its position in Asia-Pacific infant nutrition ,the purchase will greatly expand Nestle's presence in the middle- to high-end formula market in Asia-pacific.◆To enhance their infant nutrition businessWyeth Nutrition is a dynamic, high-quality infant nutrition business that complements Nestle’s existing portfolio with strong brands in key segments and geographies. It is reported that in emerging markets, more and more womencontinue to work after giving birth, this trend is particularly evident in China. This is the annual output value of $ 30 billion, 10 percent of the annual growth rate of the baby food industry is a great impetus.It will enhance their infant nutrition business, building on their growth-focused strategy, global presence and pioneering research and development. They will be able to combine well-known brands like S-26 Gold, SMA and Promil with their existing portfolio of trusted and successful brands such as Nan, Gerber, Lactogen, Nestogen and Cerelac infant cereal.2.2 The Reasons for Wyeth◆To divest the milk business ——Wyeth's businessPfizer decided to divest its milk business to strip non-main business and concentrate on new drug research on July, 2011. This is the company's largest capital divestiture since 2006. Wyeth might be able to acquire a bigger and better customer base, or strengthen their management team. Not only does it increase turnover but it also makes economies of scale possible, thus giving companies a competitive advantage in local markets.3 The Impacts of the Acquisition3.1 The direct impacts on the two parties◆Making Nestle the largest formula provider in China.The acquisition of Pfizer's Wyeth milk powder is likely to make Nestle the largest formula provider in China. According to a CI Consulting analysis, Dumex held the largest proportion of China's formula market by July 2010, taking up 16.7 percent of it. Following the company was Mead Johnson, with 12 percent of the market, and Nestle, with 10.5 percent. In the fourth position was Abbott Laboratories, which had 7.2 percent of the market, and Wyeth, with 4.7 percent of the market, was in the fifth position.So it is a possibility for Nestle to become the largest formula provider in China.◆Increasing sales of infant formulaThe purchase will lead to annual cost benefits of $160 million and will boost earnings per share in the first full year, Nestle Chief Executive Officer Paul Bulc ke said on a conference call. The Pfizer unit will increase Nestle’s sales of infant formula to $7 billion a year from $5 billion. Euro monitor figures predict that 45 percent of the growth in the market for infant nutrition products will come from China in the next five years. The country was the source of roughlya third of the $2.1 billion in sales the Pfizer unit had in 2011.◆Causing external staff redeploymentIt is not yet known what impact the sale will have on employment at the plant in the future. However, Pfizer said all employees currently involved in the nutrition business will be transferred to Nestle, with consultations to take place where required. All of the Pfizer employees working in the unit will be transferred to Nestlé when the deal completes in the first half of 2013, subject to union consultation. Pfizer also determined Nestle was a safer home for its employees, added another person familiar with the matter.3.2 The expected impacts on Chinese baby milk formula market◆H aving a greater say for foreign brands in Chinese marketThe acquisition is also expected to improve the company's dairy production lines and give it more say in pricing. Foreign brands of milk formula, faced with greater competition, are likely to become more powerful about pricing their products.◆Causing infant formulas Quality RisesDomestic companies, meanwhile, are likely to come under greater pressure as their foreign rivals become stronger. Chinese brands must insist on perfect quality and no shortcuts. The baby formula scandles of the past has convinced 90% of all mothers that the western brands are safer. Domestic companies have to through raising the product quality and quality economic , the brand advantage of the company’s products is guarante ed , in order to occupy a tiny space in the fierce market competitionTo sum up，this acquisition underlines Nestle’s commitment to be the world’s leading nutrition, health and wellness company. Wyeth’s strong brands and product portfolio, its talented people dedicated to the success of its business, together with its geographic presence - 85% of its sales are in emerging markets - will complement their existing infant nutrition business perfectly. The combined entities will enable Nestle to deepen their engagement with consumers, offering them a wider choice of nutritious food to ensure their children make a healthy start to a healthy life.(Total: 1464 words)Reference(1)China Daily “Nestle's acquisition to alter baby-food market” ( Update April 25,2012) [Online] Available at:/business/2012-04/25/content_25231403.htm[Accessed May 7, 2012](2)CCTV news content “China-Wyeth/Nestle/Acquisition ”( Update May 7, 2012) [Online] Available at:/news.jsp?fileId=139265 [Accessed May 7, 2012](3)REUTERS “EXCLUSIVE-Nestle, Danone early leaders to land $10 bln Wyeth” (Update August18, 2011) [Online] Available at:/article/companyNews/idUKL5E7JI2K320110818?symbol=ABT[Accessed May 7, 2012](4)China economic review ( Update August 9, 2011) [Online] Available at:/content/nestle-rumored-be-preparing-acquisition-pfizer%E2%80%99s-baby-n utrition-unit [Accessed May 7, 2012](5)Nestle home page ( Update May 7, 2012) [Online] Available at:/AboutUs/Pages/AboutUs.aspx [Accessed May 7, 2012](6)Pfizer home page ( Update May 8, 2012) [Online] Available at:/welcome/ [Accessed May 8, 2012]。

飞利浦光源介绍

飞利浦光源介绍许晓景 OEM技术支持照明光源固体发光光源白炽灯 (热辐射光源) 场致发光灯真空灯充气灯卤钨灯充气灯泡荧光灯电光源半导体发光灯LED 低气压灯弧光放电灯紧凑型荧光灯 QL灯低压钠灯气体放电发光光源高压汞灯高气压灯霓虹灯氖灯高压钠灯金卤灯高压氙灯碳弧灯其他2辉光放电灯表示灯泡光电性能的主要技术参数Main parameters of lamp • • • • • • • 功率(power) 瓦 (W) 光通量(Lumen output) 流明 (lm) 色温(color temp.) 开 (K) 显色指数(color rendering) Ra 寿命aver. Life) 小时 (h) 发光效率(efficiency) 流明/瓦(lm/W) 光通维持率 maintenance %3飞利浦荧光灯介绍及其创新内容简介• TL荧光灯介绍– T5荧光灯介绍及趋势 • 紧凑型荧光灯介绍– 一体化紧凑型荧光灯 – 分离式紧凑型荧光灯• 总结5飞利浦荧光灯产品线结构LAMPS GLS Halogen环管TLCFL直管HIDTLETLE 54T5Master T5 HE Master T5 HO ES T5 Mini T5 TLD std C2S TLD reflexT8TLD super 80 TLD secura TLD 90 delux6管径的比较T12 T8 T57T5 光源及其应用趋势简介应用趋势应用主要趋势 • 更自由的应用场所 • 间接照明 • 小型化设计 • 节能化设计 • 重视光线质量 • 优化替换（超长寿命减少替换） • 光色由黄光向白光转换（4000K)• 可调光（亮度，光色） • 高流明输出9TL5 特点16mm 直径，适应更小设计 HE (14, 21, 28, 35W) & HO (24, 39, 49, 54, 80W) 冷室技术，使最高光效达 104lm/W 低汞 (1.4 or 3.0mg)，更加环保三基色涂粉(/80 and /90 colors) 平均寿命24k 小时只适用电子整流器不同的灯脚 (G5 instead of G13)10BENEFITS TL5改进的光学表现带来新的设计可能小型化：16mm直径带来更紧凑更舒适的照明成本降低: 长寿命 (24k hours) 以及几乎持久的光输出更高的灯具效率 (TL-D: 25oC) 节能达到 40% 环保: 只有3mg含汞量需要更小的空间和更少的包装材料11环境温度对灯管性能的影响（冷室技术）Relative values % → 140 T8 T5 100602020 30 40 50Tambient (draught-free air) °C →12BENEFITS TL5ALMOST CONSTANT LIGHT OUTPUTLumen in % → 100 90 80 70 60 50 0 4000 8000 12000 16000 2000090Burning hours →Almost constant light output during entire lifespan Max. decrease of 10%13飞利浦紧凑型节能灯介绍飞利浦紧凑型荧光灯产品线结构LAMPS GLS Halogen民用CFLTL专业HIDCFL-IEssential Ambiance Genie TornadoCFL-IMaster SLE Master PLEU PL-S PL-C PL-L PL-TCFL-NIPL-LJ PL-F PL-H PL-QMaster EcoHLDecoTwist15一体化紧凑型荧光灯专业产品系列适应各种环境 Í 汞齐技术超常寿命达10,000 小时节电 80% 宽电压设计:170-250V 符合 IEC标准• • •低业主总成本寿命从 8,000 小时提高到 10,000 小时运用汞齐技术– 更佳流明维持率 – 适应各种环境温度 (室内&室外)17什么使得Master CFL-I从同类产品中脱颖而出?1. 在同类中有最佳的温度性能– 汞齐技术的应用保证在不同应用场合都能达到高流明输出2. 最优化的总体成本– – 长的寿命和高的光通维持率:减低了需要置换灯的成本可靠的工作使批量置换变为可能18汞齐技术应用于MASTER规格• 稳定的光输出– 应用于室内&室外 – 在相同的照度级别下需要的灯数量更少 – 较低的汞含量• 更好的光通维持率19MASTER PLEU• • • • 低业主使用总成本 10,000寿命汞齐技术高光效20MASTER SLE(D)•防眩光外罩•低业主使用总成本•10,000寿命•汞齐技术•高光效Ecotone2005（大功率一体化节能灯）: 10,000 小时民用产品系列替代灯泡ÍGenie, Ambiance长寿(确保使用三年)节电达80%宽幅电压设计: 170-250V符合IEC标准Essential•Mature product in CFL portfolio, cash cow •No new product development, focus on quality •Cost drive in purchasing•Defend market share, lower price if needed特点•高性价比•三年使用寿命•适用民用应用场所Strategy•Product in growth phase, as is market growth => Star •Controlled price reduction to take over Essential•Technical development: increase quality levels, make all versions available to all NLO ’s •Grow market share, price premium over EssentialGenie•最小的外形•三年使用寿命(6,000hrs) •理想的灯泡替代产品Strategy•New product launch in HV APR (early & rapid growth)•High market growth expected, share still relatively low (qualification: question mark) => grow share •Upgrade in portfolio, priced at premium from high Wattage Essentials 18W & 23W •Innovation medium term: smaller size (T2 burner)Tornado•紧凑外形，高流明输出•装饰性“螺旋形”外形新增加产品系列DecoTwist•直接安装•T5分离式紧凑型荧光灯PL-LPL-C600 -1800 lmRedesignedPL-T飞利浦T5C产品线分布及流明输出PL -接桥技术的影响PL-C Master 特性接桥位置的优化:•实际使用中光通量提高了6%•提高了系统的温度特性先进的飞利浦保护膜技术:•灯的寿命从8000提高到了10000小时•光通维持率得到提高，保证寿命期间稳定光通输出•同样的投入，12％的额外光通2 -4 mm 4 -8 mm比竞争对手多了18%的光通PL-S rangeRange E cotoneProduct type P L-SU SP B ridge technologyBenefits- Low cost of ownership- Long life (8,000 hours)Application E mergency lighting, consumerluminairs, downlightingTarget market P rofessional end users, hospitalityW hy in portfolio ?Replacement product, stablemarket. OE M opportunitiesCompetition OsramPL-C rangeRange E cotoneProduct type P L-C MASTERU SP B ridge technologyBenefits- Higher Lumen output- Low cost of ownership- Long life (10,000 hours)Application DownlightingTarget market P rofessional end users, hospitalityW hy in portfolio ?Unique features in fast growingdown-lighting segmentCompetition Osram Dulux, GE B iaxPL-L rangeRange E cotoneProduct type P L-L MASTERU SP B ridge technologyBenefits- Higher Lumen output- Low cost of ownership- Long life (12,000 hours)Application Office (TL) luminaires, recessedTarget market P rofessional end users, hospitalityW hy in portfolio ?High Lumen, compact alternativefor TL applications (T5!)Competition Osram Dulux, GE B iaxPL-T rangeRange E cotoneProduct type P L-TU SP Amalgam technologyBenefits- S table Lumen output- Low cost of ownership- Long life (15,000 hours)Application E mergency lighting, downlightingTarget market P rofessional end users, hospitalityW hy in portfolio ?Offers high Lumen options in downlightersCompetition Osram Dulux T, GE B iax Q灯管设计改变(由弯管变为直管-使用冷端技术-瓦数增大到-更小灯座新PL-T的优势优势:全新设计•对称的外形•小灯脚•小的尺寸•可以替代所有竞争者的类型优势PL-T 42wStandard 42wPLTSelect the right lamp for the best performance of your lighting installation.MASTER PL-TMASTER PL-T (with Cold Spot technology)Select the right lamp for the best performance of your lighting installation.Marketing & Business Development Light PJL Confidential60W 4000 lm/830 and /84085W 6000 lm120W 9000 lmMaster PL-H rangePL-H luminairesPL-Q Pro配合灯具适合走廊，厕所，电梯间，接待处等场所照明灯脚: 2GX13管径: 16mm(比TLE管径细55%）使用电子整流器22W40W55W60WT5C产品规格TL5C。

MTU ONSITE ENERGY

© MTU Onsite Energy GmbH All rights reserved
01. OUR VISION AND STRATEGY
Vision
We at Tognum set the standard as the preferred partner for the best solutions in power and propulsion.
LuftfahrzeugMotorenbau GmbH
L’Orange
DaimlerChryslerOff-Highway
Tognum „Home of Power Brands”
100 years MTU
MTU Friedrichshafen
Independent Group
IPO
MTU Onsite Energy
S 4000 S 2000 S 1600
450 750 1,000 2,000 3,000
Series 1600 Utilisation of MTU engines
Strategy
Maintaining leadership in product innovation. Broadening application and customer portfolio. Custom-made products. Integrating system and service offerings.
06. PRODUCT PORTFOLIO
AN EXCELLENT PRODUCT RANGE COVERAGE
Series 4000
Utilisation of MTU engines and third parties´ engines

美国联合保健公司产品说明书：测试生成产品

UnitedHealthcare PharmacyClinical Pharmacy ProgramsProgram Number 2023 P 2018-16Program Prior Authorization/Medical Necessity – TestosteroneMedication Androderm, Androgel*, Fortesta*, Jatenzo*, Natesto*, Kyzatrex*,Testim, testosterone topical solution (generic Axiron)*, testosteronetransdermal gel (generic Testim)*, Tlando*, Vogelxo*, Xyosted*P&T Approval Date 2/2014, 4/2014, 5/2014, 7/2014, 10/2014, 10/2015, 5/2016, 6/2017,6/2018, 2/2019, 6/2019, 7/2020, 8/2021, 9/2022, 1/2023Effective Date 4/1/2023;Oxford only: 4/1/20231.Background:Testosterone products are approved by the Food and Drug Administration (FDA) for testosterone replacement therapy in males with primary hypogonadism (congenital or acquired) orhypogonadotropic hypogonadism (congenital or acquired). Primary hypogonadism originatesfrom a deficiency or disorder in the testicles. Secondary hypogonadism indicates a problem in the hypothalamus or the pituitary gland. Testosterone use has been strongly linked to improvements in muscle mass, bone density, and libido.The purpose of this program is to provide coverage for androgens and anabolic steroid therapy for the treatment of conditions for which they have shown to be effective and are within the scope of the plan’s pharmacy benefit. Coverage for the enhancement of athletic performance or bodybuilding will not be provided.a3.Additional Clinical Rules:•Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)and/or claim logic. Use of automated approval and re-approval processes varies by programand/or therapeutic class.•Supply limits may be in place.•* May be excluded from coverage•+ Coverage for patient population may be dependent upon benefit design4.References:1.AACE Hypogonadism Task Force. American Association of Clinical EndocrinologistsMedical Guidelines for Clinical Practice for the Evaluation and Treatment ofHypogonadism in Adult Male Patients – 2002 Update. Endocr Pract. 2002; 8(No. 6): 439-456.2.The World Professional Association for Transgender Health (WPATH), Standards of Carefor the Health of Transsexual, Transgender, and Gender Nonconforming People, 7thVersion.3.Cook, David M, et al. "American Association of Clinical Endocrinologists medicalguidelines for clinical practice for growth hormone use in growth hormone-deficient adultsand transition patients - 2009 update: executive summary of recommendations." Endocrinepractice 15.6 (2009):580-586.4.Gibney, James, et al. "Growth hormone and testosterone interact positively to enhanceprotein and energy metabolism in hypopituitary men." American journal of physiology:endocrinology and metabolism 289.2 (2005):E266-E2715.Bhasin, S, et al. "Testosterone replacement and resistance exercise in HIV-infected menwith weight loss and low testosterone levels." JAMA. 2000. 283.(6) 763-770.6.Isidori, Andrea M, et al. Effects of testosterone on sexual function in men: results of ameta-analysis. Clinical endocrinology. 2005 63(4):381-394.7.Kenny, A M, et al. Effects of transdermal testosterone on bone and muscle in older menwith low bioavailable testosterone levels. The journals of gerontology. 2001. 56(5) M266-M272.8.Tracz, Michal J, et al. Testosterone use in men and its effects on bone health. A systematicreview and meta-analysis of randomized placebo-controlled trials. The Journal of clinicalendocrinology and metabolism. 2006. 91(6):2011-2016.9.Bolona, Enrique R, et al. Testosterone use in men with sexual dysfunction: a systematicreview and meta-analysis of randomized placebo-controlled trials. Mayo Clinicproceedings.2007. 82(1):20-28.10.Androderm [package insert]. Madison, NJ: Allergan, Inc; May 2020.11.Androgel [package insert]. North Chicago, IL: AbbVie Inc; May 2020.12.Fortesta [package insert]. Malvern, PA: Endo Pharmaceuticals Inc; January 2022.13.Testim [package insert]. Malvern, PA: Endo Pharmaceuticals Inc; August 2021.14.Natesto [package insert]. Mississauga, ON: Acerus Pharmaceuticals Corporation;December 2021.15.Vogelxo [package insert]. Maple Grove, MN: Upsher-Smith Laboratories, LLC; April2020.16.Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline.J Clin Endocrinol Metab 2017; 102:3869.17.The Endocrine Society. Testosterone therapy in Adult Men with Androgen DeficiencySyndromes. J Clin Endocrinol Metab, May 2018, 103(5):1–30.18.Mulhall JP, et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline.American Urological Association Education and Research, Inc 2018.19.Xyosted [package insert]. Ewing, NJ: Antares Pharma, Inc; November 2019.20.Jatenzo [package insert]. Northbrook, IL: Clarus Therapeutics, Inc; March 2019.21.Tlando [package insert]. Ewing, NJ: Antares Pharma, Inc; March 2022.22.Kyzatrex [package insert]. Raleigh, NC: Marius Pharmaceuticals LLC; September 2022.Program Prior Authorization/Medical Necessity - TestosteroneChange ControlDate Change2/2014 Create Prior Authorization Criteria4/2014 Revised Reauthorization Criteria; formatting corrections, referencesupdated.5/2014 Revised the initial authorization criteria to include subsections for themale population and the female to male transsexual population, updatedto include language from the gender identity disorder/ gender dysphoriatreatment medical coverage determination guideline, referencesupdated7/2014 Added Natesto and Vogelxo to criteria. Changed coverage criteria fromspecific product names to topical testosterone products.10/2014 Modified criteria for total testosterone to consider reference range of thelaboratory. Added criteria for when Free Testosterone level may beutilized. Added criteria for conditions that do not require testosteronelevels. Extended initial authorization period for patients already ontherapy.12/2014 Testosterone free level units corrected.10/2015 Clarified initial authorization periods. Clarified that levels forreauthorization should be within the past 6 months for patients new totestosterone and within the past 12 months for continuing users.Updated references.5/2016 Removed age requirement from female to male transsexual coveragerequirements. Updated gender identity disorder to gender dysphoria.6/2017 Updated criteria for Gender Dysphoria. Updated reauthorizationcriteria to clarify that new to therapy refers to use of less than one yearand continuing therapy refers to use of one year or longer.6/2018 Updated required testosterone level to less than 300 ng/dL based on2018 American Urological Society treatment guidelines.2/2019 Program name change from Topical Androgens to Testosterone.Xyosted added to program.6/2019 Jatenzo added to program.7/2020 Updated initial authorization to 6 months for both new and existingusers. Added state mandate language. Updated references.8/2021 Annual review. Updated references. Removed Striant as it is no longeron the market.9/2022 Tlando added to program. Removed brand Axiron from program sinceit is no longer available. Updated to note generic Testim is typicallyexcluded. Updated references.1/2023 Kyzatrex added to program. Increased initial authorization to 12months and changed reauthorization to require a lab value within thepast 12 months.。

D1-心脏生理解剖结构和传导路径ppt课件

bster EP Training 2003 y, Conduction System, Positions
BW产品综述
Slide 1
7/6/2024
电生理培训（一）
心脏解剖结构、电传导路径导管定位
bster EP Training 2003 y, Conduction System, Positions
Positions
冠状窦心尖
Slide 38
7/6/2024
电生理检查
心内心电图前传测试
前传
从高位右房起搏
逆传
bster EP Training 2003 y, Conduction System, Positions
从右室心尖起搏
Slide 39
7/6/2024
Slide 4
7/6/2024
左室上腔静脉主动脉弓左上肺静脉左下肺静脉
右房下腔静脉
右室
bster EP Training 2003 y, Conduction System, Positions
Slide 5
7/6/2024
主动脉
房间隔
卵圆窝
bster EP Training 2003 y, Conduction System, Positions
bster EP Training 2003 y, Conduction System, Positions
P wave - Atrial Depolarisation
QRS - Ventricular Depolarisation
PR interval - time taken for the impulse to be conducted from the SA node to the Purkinjie

新一代降糖药gosogliptin

.
2012 THOMSON REUTERS. For more information go to /copyright/
.
2007, and the study was expected to complete in June 2008 [ 868416]. In June 2009, data from the trial were presented at the 69th ADA scientific sessions in New Orleans, LA. A total of 289 patients were treated with 20 or 30 mg of gosogliptin qd or placebo. At week 12, both doses significantly reduced HbA1c compared with placebo, with 55.8 and 52.2% of patients in the 20 and 30 mg dose groups, respectively, achieving HbA1c less than 7% compared with only 23.8% of the placebo group. The drug was well tolerated with the most common adverse events being pain in extremity, pharyngolaryngeal pain, headache and dyspepsia [1013516 ].
Target
Dipeptidyl peptidase IV
Update date
17-JUL-2012
Reason for update

三星和博世SBL动力电池介绍

- Pack Development (Stuttgart) - Sales & Marketing (Stuttgart)
- Pack Development (Orion, MI) - Pack Manufacturing (Springboro, OH)
Page 3
Foton & SB LiMotive Meeting
Page 10
Foton & SB LiMotive Meeting
④ Cost Competitiveness Experience from IT Battery Business
Last 10 years, as energy density doubled and sales volume increased
96
CAGR=28%
65
73
Tianjin
Cheonan
34 22 38
54
Shanghai
Dongguan
2005 2006 2007 2008 2009 2010
Polymer
2011
Cylindrical
Prismatic
Tianjin
Page 9
Foton & SB LiMotive Meeting
[ Inauguration Ceremony in Nov. 2010 ]
Page 4
Foton & SB LiMotive Meeting
Ulsan Plant
Complex for Suppliers SDI New Factory
Total Campus : 2,300,000 sqm
SBL Space : 13,000 sqm (Floor Space : 40,000 sqm) - Future Space : 50,000 sqm Construction Period : 9 Months (Sep. 2009 ~ May. 2010)

1、下载文档前请自行甄别文档内容的完整性，平台不提供额外的编辑、内容补充、找答案等附加服务。
2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
3、如文档侵犯您的权益，请联系客服反馈,我们会尽快为您处理(人工客服工作时间：9:00-18:30)。

Fuel Performance Efficiency
Target Vehicles: Global A & B segments
Reduced Emissions
10
CONFIDENTIAL INFORMATION
DualTronic™ DT170CT
11
CONFIDENTIAL INFORMATION
PTM®
Part-Time
Open Diff
Ford Explorer Mercury Mountaineer
Cadillac CTS
BMW 330XI Demonstrator
Audi Q7 Ford F-Series Hummer H3
GMC Savana
KIA Borrego Ford Expedition Lincoln Navigator …..and many more Ford Ranger Mazda B-Series Chrysler 300, Dodge Charger Drivetrain TATA Safari, Sumo, Sierra …..and many more Cadillac Escalade GMC Yukon Denali …..and many more Cadillac STS & SRX
• Speeds: Single
• Available reduction ratios:
• 6.54**, 7.17, 8.00, 8.28**, 8.76, 9.07
• Efficiency: >97% (targeted)
• Rated input torque: ~200 Nm continuous (300 Nm peak)
Porsche 911 Turbo
Cadillac CTS
Electronic Shift Transfer Case with BW Controls & ECU: 3.4 Million + produced
(2007 SOP)
GM H2
GM H3
SsangYong Rexton, Musso, Korando
High RPM Concentric Dual Clutch
CONFIDENTIAL INFORMATION
High RPM Parallel Dual Clutch
5
Drivetrain Product Portfolio
Low Pressure Solenoids and Control Systems
12
CONFIDENTIAL INFORMATION
i~Trac™ Front-Wheel Drive AWD Portfolio
Active OnDemand Twin Active On-Demand
ITM 3e™
Drivetrain
NexTrac™
PTM™
T-Trac™
Drivetrain
Dodge Journey
NexTrac™ 100
Key enabler for smaller more fuel efficient AWD
Features • Direct electro-mechanical actuation • Organic primary clutch material • Tunable torque capacity and drag torque • Reduced mass spin loss, rotating inertia Benefits • Optimal vehicle system integration and assembly • Outstanding lifetime NVH performance • Low drag torque and reduced weight enables fuel economy benefits
• Max input speed: ~14,000 rpm • Center distance: 210 mm • Lubrication: Splash • Park lock system
• Electric park pawl actuation (CAN enabled) • Mechanical actuation option
Drivetrain Product Portfolio
DualTronic™ Dual Clutch Modules
Concentric Dual Clutch
Integrated Dual Clutch / Wet Dual Mass Flywheel
High Torque Parallel Dual Clutch
8 CONFIDENTIAL INFORMATION
Drivetrain Product Portfolio
High Pressure Solenoids and Control Systems On-Demand Electro-Hydraulic System
Responsive, efficient, compact: • Solenoid module sub-assembly • High pressure, very low leak solenoids • Proven in 10+ years of AMT use • Hybrid powertrain compatibility • Accumulator pressure supply • Electric pump on demand Dry DCT application launches 2010
14
CONFIDENTIAL INFORMATION
Rear-Wheel Drive AWD Portfolio
Active Torque-On-Demand® Systems
Torque-OnDemand®
Passive Systems
TorqueSensing SpeedSensing
ITM® tc
Drivetrain Product Portfolio
Friction and Clutching Systems
Clutch Modules
Clutch Plates
One-Way Clutches
Brake Bands
CONFIDENTIAL INFORMATION
Torque Converter Clutches 4
Hyundai Santa Fe
Audi A3 Demonstrator
Honda Ridgeline
Kia Sportage
HUATAI (China)
Honda Pilot
Hyundai Tucson Cherry Tiggo
Porsche 911 Turbo
13
CONFIDENTIAL INFORMATION
Step A/T Solenoid Module
CONFIDENTIAL INFORMATION
DCT Control Module
7
Drivetrain Product Portfolio
MDA - Mini Direct-Acting Variable Force Solenoid
Low-Flow VFS for pilot control function Designed to be direct replacement for variable bleed solenoids Reduced leakage and greater accuracy provides improved fuel economy and shift quality
15
CONFIDENTIAL INFORMATION
Electronic Controls: Applications
FWD On-Demand AWD with BW Controls & ECU: 1 Million + produced
(2007 SOP)
Hyundai Santa Fe
Hyundai Tucson
Mahindra Bolero, Scorpio
TATA Safari, Sumo, Sierra
Kia Borrego
16
CONFIDENTIAL INFORMATION
31-03 eGearDrive™
Electric Drive Transaxle
Technical Features
• Mass: 28Kg*
Automatic Transmission Technology
Sห้องสมุดไป่ตู้ep A/T
Friction and Clutching Systems Solenoids and Control Systems
CVT
Friction and Clutching Systems Solenoids and Control Systems
On/Off Solenoids
2-Position Solenoids
PWM Solenoids
Variable Bleed Solenoids (VBS) Proportional Solenoids (Variable Force Solenoids – VFS) Direct-Acting Solenoids (DA VFS)
System Integration
BWUTS DualTronic Modules
Vehicle Integration and Calibration
Transmission Testing and Validation